

Drug Repurposing Guidebook

Building Block 1433

This document defines the content of the FACT SHEET to be created for each identified tool, incentives, initiative or practice (the Building Block) introduced by public bodies or used by developers to expedite drug repurposing in Rare Diseases (RDs).

ITEM	DESCRIPTION
Building Block (BB) Title	CURE ID
References	- https://cure.ncats.io
Description	Describes case reports where drugs have been repurposed to treat infectious diseases lacking adequate approved treatments. Cases include those contributed by clinicians around the world via the short electronic case report form, as well as those extracted from published articles, found via systematic literature reviews in Pubmed. Also includes a treatment discussion forum, newsfeed with daily journal and news articles on drug repurposing in infectious diseases and a calendar of events. Clinical trials are also pulled from clinicaltrials.gov where applicable.
Category	Availability of data
Type of BB	Development practice
Geographical scope	International
Availability	Available to anyone and anytime. Free website and mobile app including offline access for use in resource-limited settings.
Scope of use	Limited – specific to infectious diseases (currently), expansions to replicate the platform in rare diseases (including rare cancers) and diseases affecting specific populations (e.g., neonates and pregnant individuals) is underway



DESCRIPTION
Clinicians, patients, regulators, researchers, policymakers, drug developers, funders
Access to the internet to initially download the app or view the website
A treatment registry of close to 5000 cases of treatment of infectious diseases with repurposed drugs (many for rare infectious diseases). New implementation of a patient portal that allows patients to enter their own case reports, in addition to those from clinicians.
Any time
Contact Heather Stone heather.stone@fda.hhs.gov for more information or to get involved.
Can download the mobile app on the App or Play Store by searching for "CURE ID"
Is a joint initiative of U.S. FDA and NIH, with support from the Critical Path Institute, who have convened an associated public-private partnership – the CURE Drug Repurposing Collaboratory (CDRC) – www.c-path.org/cdrc
Also in partnership with WHO, IDSA, JHU, SCCM, IDDO/Oxford, Emory
A case report on use of a repurposed drug can be submitted in less than 3 minutes